Tuhura Biosciences, Inc/nv Form 4 insider transactions

Kintara Therapeutics and TuHURA Biosciences have entered into a waiver agreement, modifying their merger agreement by waiving the requirement for Kintara stockholder approval of both the reincorporation of Kintara from Nevada to Delaware and an increase in authorized shares, contingent upon a reverse stock split.

Kintara Therapeutics has adjourned its Special Meeting of Stockholders to October 4, 2024, due to insufficient voting power on key proposals related to the proposed merger with TuHURA Biosciences, urging stockholders to vote before the extended deadline.

Kintara Therapeutics has adjourned its Special Meeting of Stockholders to October 4, 2024, to allow more time for stockholders to vote on proposals related to the proposed merger with TuHURA Biosciences, including increasing authorized shares and reincorporating in Delaware.

Kintara Therapeutics and TuHURA Biosciences used social media to update stockholders about the upcoming Special Meeting to approve their proposed merger.

Kintara Therapeutics is reminding stockholders to vote by September 19, 2024, to approve the proposed merger with TuHURA Biosciences.

Kintara Therapeutics is urging stockholders to vote in favor of the proposed merger with TuHURA Biosciences, citing potential bankruptcy and clinical trial suspension if the merger is not approved.

Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences at the upcoming Special Meeting.

Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences, emphasizing the potential consequences of not approving the merger.

Kintara Therapeutics and TuHURA Biosciences announce that Kineta has reopened enrollment in its VISTA-101 Phase 1/2 clinical trial for KVA12123 in advanced solid tumor cancer patients.

TuHURA Biosciences secures an exclusive right to acquire Kineta's KVA12123, a novel anti-VISTA checkpoint inhibitor, for a potential $5 million deal.

Kintara Therapeutics and TuHURA Biosciences provide an update on their recent corporate and clinical advancements, including the planned merger and clinical trial progress, and outline expected near-term milestones.

Kintara Therapeutics secures a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement while pursuing a merger with TuHURA.

TuHURA Biosciences and Kintara Therapeutics reported positive results from a Phase 1b trial of IFx-2.0, a personalized cancer vaccine, showing promising efficacy in patients with advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma resistant to checkpoint inhibitors.

Kintara Therapeutics reported its Q3 2024 financial results, highlighting a merger agreement with TuHURA Biosciences and progress in its REM-001 study.

TuHURA Biosciences' IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting, coinciding with updates on the proposed merger with Kintara Therapeutics.

Kintara Therapeutics and TuHURA Biosciences have entered into a definitive merger agreement to form a company focused on advancing novel technologies to overcome resistance to cancer immunotherapy.